ROIV
NASDAQ · Biotechnology
Roivant Sciences Ltd
$34.01
+1.80 (+5.59%)
Financial Highlights (FY 2026)
Revenue
8.56M
Net Income
-310,724,803
Gross Margin
84.4%
Profit Margin
-3,629.2%
Rev Growth
-48.7%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 84.4% | 84.4% | 53.5% | 53.5% |
| Operating Margin | -6,102.2% | -5,492.0% | -4.7% | -4.6% |
| Profit Margin | -3,629.2% | -3,447.7% | -5.1% | -4.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 8.56M | 16.69M | 2.76B | 2.29B |
| Gross Profit | 7.23M | 14.10M | 1.47B | 1.22B |
| Operating Income | -522,305,786 | -916,862,117 | -129,388,409 | -105,547,959 |
| Net Income | -310,724,803 | -545,450,210 | -140,854,131 | -104,632,272 |
| Gross Margin | 84.4% | 84.4% | 53.5% | 53.5% |
| Operating Margin | -6,102.2% | -5,492.0% | -4.7% | -4.6% |
| Profit Margin | -3,629.2% | -3,447.7% | -5.1% | -4.6% |
| Rev Growth | -48.7% | -48.7% | -1.7% | -7.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 7.19B | 7.29B |
| Total Equity | — | — | 12.91B | 14.47B |
| D/E Ratio | — | — | 0.56 | 0.50 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -519,025,505 | -961,720,752 | -182,068,335 | -161,653,425 |
| Free Cash Flow | — | — | -125,369,781 | -83,019,830 |